Global Markets Eye Novartis’ $12 Billion Biotech Acquisition, Easing U.S.-China Trade Tensions, and Sony’s M&A Stance

By / / Breaking News

Key Takeaways

  • Novartis AG (NVS) will acquire Avidity Biosciences (RNA) for $12 billion in cash, representing a 46% premium, significantly bolstering its late-stage neuroscience and RNA therapeutics pipeline.
  • China has committed to making "substantial" purchases of U.S. soybeans, a move signaling easing trade tensions and offering relief to U.S. farmers ahead of a planned Trump-Xi summit.
  • Sony Group (SONY) has clarified it has no immediate desire for major M&A deals in the U.S. film industry and specifically denied any intention to bid for Warner Bros Discovery (WBD).

Global financial markets are reacting to a flurry of significant corporate and geopolitical developments, including a major pharmaceutical acquisition, a de-escalation in U.S.-China trade relations, and a clear statement on M&A strategy from a Japanese tech giant.

Swiss pharmaceutical giant Novartis AG (NVS) announced its intent to acquire Avidity Biosciences (RNA) for a substantial $12 billion in an all-cash deal. This acquisition prices Avidity shares at $72 each, marking a 46% premium over its recent closing price. The strategic move is expected to significantly expand Novartis's late-stage neuroscience and RNA therapeutics pipeline, as the company actively seeks new growth avenues amidst expiring drug patents. The deal is projected to close in early 2026, specifically in the first half of the year, subject to regulatory and shareholder approvals. Prior to the merger, Avidity will spin off its early-stage precision cardiology programs into a new entity, SpinCo, which will be capitalized with $270 million.

Meanwhile, U.S.-China trade tensions appear to be easing following high-level talks in Kuala Lumpur. Treasury Secretary Scott Bessent confirmed that China is poised to make "substantial" purchases of U.S. soybeans, a development expected to provide much-needed relief to U.S. farmers who have been impacted by previous trade disputes. This positive step comes ahead of a planned summit between President Trump and President Xi Jinping, where a broader trade agreement is anticipated. Bessent also indicated that the threat of 100% tariffs on Chinese goods is "effectively off the table" and that China is expected to defer its rare earth export controls.

In the entertainment sector, Sony Group (SONY) has dampened speculation regarding major acquisitions in the U.S. film industry. According to Nikkei, the Sony Group CEO stated there is no current desire for big mergers and acquisitions. Specifically, the company denied any intention of bidding for Warner Bros Discovery (WBD), putting an end to recent market rumors.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.
Scroll to Top